BeiGene, Ltd.

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.In 2017, we entered into a strategic collaboration with Celgene Corporation, or Celgene, in which we granted Celgene exclusive rights to develop and commercialize tislelizumab for solid tumors in the United States, Europe, Japan, and the rest of the world outside of Asia. We retained rights to tislelizumab for solid tumors in Asia (ex-Japan) and for hematological malignancies and internal combinations globally.

Bank Name BeiGene, Ltd.
Stock Exchange NASDAQ
Symbol BGNE
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman Mr. John V. Oyler
CEO Mr. John V. Oyler
Employees 900
Registered Year 2010